Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges - Takeaways - MDSpire

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • By

  • Sirajunisa Talath

  • Mohamed El-Tanani

  • Adil Farooq Wali

  • Syed Arman Rabbani

  • Bhoomendra Bhongande

  • Walaa Ibraheem

  • Ashot Avagimyan

  • Karolina Hoffmann

  • Ioannis Ilias

  • Sorina Ispas

  • Maggio Viviana

  • Anna Paczkowska

  • Manfredi Rizzo

  • April 30, 2026

  • 0 min

Share

  • 1

    Breast cancer is the most common cancer among women globally, with increasing incidence and mortality rates despite advancements in treatment.

  • 2

    Natural supplements like curcumin and resveratrol show potential anticancer activity, but robust clinical evidence for their efficacy is still limited.

  • 3

    Challenges such as low bioavailability, standardization issues, and herb-drug interactions hinder the clinical use of natural supplements in breast cancer.

  • 4

    Future studies should focus on personalized dosing, standardization, and integration of natural supplements with precision oncology.

  • 5

    Multidisciplinary collaboration is essential for developing evidence-based guidelines for the safe use of natural supplements alongside traditional therapies.

Original Source(s)

Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges

  • by Sirajunisa Talath, Mohamed El-Tanani, Adil Farooq Wali, Syed Arman Rabbani, Bhoomendra Bhongande, Walaa Ibraheem, Ashot Avagimyan, Karolina Hoffmann, Ioannis Ilias, Sorina Ispas, Maggio Viviana, Anna Paczkowska, Manfredi Rizzo

  • April 30, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors